Supplier
Mainehealth
Mainehealth was paid $70.83M by Medicaid between Jan 2018 and May 2024, across 582 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 29% of everything it billed.
33Billing provider infoMAINEHEALTH
BIDDEFORD, ME 04005
BIDDEFORD, ME 04005
33aNPI1659392819assigned 07/22/2006
33bProvider typePharmacy
28Total paid$70.83M
24GClaims2,083,723
24DCodes billed582
24AFirst – last monthJan 2018 – May 2024
Compared with peers
Next to other Pharmacy providers in Maine
Rank by total paid#1 of 16
Median peer was paid$46.59
This provider vs. median1,520,322×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official INZANA, LUGENE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 347,009 | $10.56M | |
| 2019 | 323,908 | $10.33M | |
| 2020 | 263,627 | $8.59M | |
| 2021 | 332,369 | $11.60M | |
| 2022 | 334,593 | $11.91M | |
| 2023 | 333,379 | $12.23M | |
| 2024incomplete | 148,838 | $5.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 29% | 288,588 | 230,254 | $20.29M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 52,670 | 47,062 | $9.43M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.5% | 13,986 | 12,957 | $3.89M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.0% | 23,491 | 22,226 | $2.86M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 16,300 | 14,631 | $1.72M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 15,116 | 14,140 | $1.28M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 44,189 | 15,589 | $1.07M |
| 64493 | 1.5% | 2,932 | 2,815 | $1.06M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 6,450 | 6,251 | $881K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 18,150 | 17,745 | $690K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 10,587 | 10,501 | $646K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | <1% | 6,182 | 4,205 | $628K |
570 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,489 | $626K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 10,297 | $619K |
| 20610 | <1% | 5,558 | $611K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,822 | $604K |
| G0008 | Administration of influenza virus vaccine | <1% | 22,600 | $604K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 9,496 | $582K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,110 | $577K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,557 | $555K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 14,965 | $538K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,665 | $523K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,930 | $519K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,769 | $517K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 20,676 | $506K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,694 | $505K |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | <1% | 4,491 | $477K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 15,752 | $444K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 978 | $433K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 5,102 | $432K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 7,082 | $431K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 6,553 | $406K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 5,598 | $401K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 8,331 | $369K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,996 | $357K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 5,790 | $343K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,404 | $337K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,077 | $333K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,388 | $321K |
| 64635 | <1% | 525 | $318K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,270 | $291K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 1,490 | $289K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,077 | $278K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 3,642 | $264K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,619 | $261K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 845 | $259K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,699 | $235K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,039 | $230K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 15,969 | $229K |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 969 | $229K |
| 76830 | Ultrasound, transvaginal | <1% | 2,938 | $227K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,010 | $220K |
| G0009 | Administration of pneumococcal vaccine | <1% | 8,094 | $214K |
| 97161 | <1% | 5,046 | $200K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,732 | $198K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 912 | $192K |
| 70496 | <1% | 1,248 | $191K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 24,051 | $184K |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 146 | $180K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 209 | $176K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,263 | $170K |
| 80061 | Lipid panel | <1% | 24,801 | $168K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 365 | $166K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 26,827 | $162K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,781 | $157K |
| 94060 | <1% | 1,298 | $157K | |
| 59025 | Fetal non-stress test | <1% | 1,155 | $156K |
| 80053 | Comprehensive metabolic panel | <1% | 71,556 | $152K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 424 | $147K |
| 64490 | <1% | 348 | $138K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,187 | $135K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,318 | $134K |
| 86900 | <1% | 4,011 | $125K | |
| 71250 | <1% | 2,893 | $124K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,673 | $124K |
| C8930 | Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision | <1% | 455 | $122K |
| 90686 | <1% | 20,938 | $121K | |
| 90677 | <1% | 782 | $117K | |
| 93971 | <1% | 2,393 | $115K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,268 | $115K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,259 | $115K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 776 | $111K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,899 | $111K |
| 76770 | <1% | 1,729 | $105K | |
| 72141 | <1% | 716 | $98K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,073 | $96K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 73,627 | $94K |
| 10060 | <1% | 671 | $84K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,839 | $82K |
| 90732 | <1% | 1,330 | $78K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,749 | $77K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 873 | $76K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 165 | $76K |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 95 | $76K |
| 36415 | Collection of venous blood by venipuncture | <1% | 84,464 | $75K |
| 97162 | <1% | 3,041 | $74K | |
| 76642 | <1% | 1,632 | $73K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,100 | $73K |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 4,389 | $72K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,810 | $70K |
| 76536 | <1% | 1,296 | $69K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 23,214 | $65K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 934 | $62K |
| 87481 | <1% | 10,605 | $60K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 30,793 | $55K |
| 97165 | <1% | 1,650 | $55K | |
| 97597 | <1% | 1,009 | $54K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,838 | $53K |
| 29581 | <1% | 857 | $53K | |
| 97803 | <1% | 1,691 | $52K | |
| 62323 | <1% | 211 | $52K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 24 | $50K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,365 | $49K |
| 43235 | <1% | 160 | $49K | |
| 77066 | Tomosynthesis, mammo | <1% | 668 | $48K |
| 72100 | <1% | 2,051 | $46K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 25,565 | $46K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,146 | $45K |
| 74018 | <1% | 2,232 | $45K | |
| 73221 | <1% | 324 | $43K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,530 | $42K |
| 90651 | <1% | 3,685 | $42K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,987 | $42K |
| 64721 | <1% | 52 | $42K | |
| 0002A | <1% | 1,708 | $39K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,547 | $39K |
| 77080 | <1% | 1,248 | $39K | |
| 82607 | <1% | 7,420 | $39K | |
| 76801 | <1% | 429 | $38K | |
| 88142 | <1% | 3,298 | $38K | |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | <1% | 120 | $37K |
| 73562 | <1% | 4,245 | $36K | |
| 86780 | <1% | 3,131 | $36K | |
| 64615 | <1% | 291 | $35K | |
| 86003 | <1% | 909 | $35K | |
| 82728 | <1% | 5,929 | $33K | |
| 96127 | <1% | 4,238 | $32K | |
| 0001A | <1% | 1,686 | $32K | |
| 0011A | <1% | 1,257 | $32K | |
| 90870 | <1% | 213 | $32K | |
| 0012A | <1% | 1,230 | $32K | |
| 20611 | <1% | 292 | $32K | |
| 73030 | <1% | 4,645 | $32K | |
| 77065 | Tomosynthesis, mammo | <1% | 614 | $32K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,755 | $31K |
| 93880 | <1% | 492 | $31K | |
| 99495 | <1% | 726 | $31K | |
| 73630 | <1% | 4,797 | $31K | |
| 87511 | <1% | 5,397 | $30K | |
| 86803 | <1% | 5,461 | $30K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,332 | $30K |
| 97802 | <1% | 570 | $30K | |
| 90670 | <1% | 5,983 | $29K | |
| 99188 | <1% | 1,173 | $29K | |
| 95811 | <1% | 55 | $28K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 5,473 | $28K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 255 | $28K |
| G0010 | Administration of hepatitis b vaccine | <1% | 869 | $28K |
| 85027 | <1% | 16,690 | $28K | |
| 82746 | <1% | 5,591 | $28K | |
| 73502 | <1% | 3,079 | $27K | |
| 98929 | <1% | 2,334 | $27K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 29 | $26K |
| 98928 | <1% | 2,845 | $25K | |
| 93225 | <1% | 599 | $25K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,407 | $24K |
| D1206 | Topical application of fluoride varnish | <1% | 4,022 | $23K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 253 | $23K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 859 | $22K |
| 71271 | <1% | 376 | $22K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 704 | $22K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,296 | $21K |
| 97166 | <1% | 1,296 | $21K | |
| 93970 | <1% | 217 | $21K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 106 | $20K |
| 83655 | <1% | 4,324 | $20K | |
| 91320 | <1% | 607 | $20K | |
| 87522 | Neg quan hep c or qual rna | <1% | 856 | $19K |
| 17110 | <1% | 429 | $19K | |
| 83550 | <1% | 5,674 | $19K | |
| 85610 | <1% | 16,397 | $19K | |
| 94010 | <1% | 352 | $18K | |
| 84702 | <1% | 3,320 | $18K | |
| 73130 | <1% | 2,847 | $18K | |
| 74174 | <1% | 126 | $18K | |
| 74183 | <1% | 111 | $18K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,377 | $18K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,751 | $18K |
| 73110 | <1% | 2,991 | $18K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,045 | $18K |
| 83540 | <1% | 6,375 | $17K | |
| 83970 | <1% | 1,145 | $17K | |
| 73600 | <1% | 1,695 | $17K | |
| 84439 | <1% | 4,177 | $16K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,220 | $16K |
| 12001 | <1% | 1,020 | $16K | |
| 0054A | <1% | 846 | $16K | |
| 80076 | <1% | 4,663 | $15K | |
| 97116 | <1% | 2,325 | $15K | |
| 87070 | <1% | 11,148 | $15K | |
| 97014 | <1% | 1,128 | $15K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 645 | $14K |
| 84403 | <1% | 1,003 | $14K | |
| 93017 | <1% | 789 | $14K | |
| Q3014 | Telehealth originating site facility fee | <1% | 967 | $14K |
| 73610 | <1% | 3,024 | $14K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 308 | $14K |
| 70486 | <1% | 412 | $14K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 982 | $13K |
| 94660 | <1% | 243 | $13K | |
| 58300 | <1% | 385 | $13K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 816 | $12K |
| 69209 | <1% | 1,326 | $12K | |
| 83735 | <1% | 19,669 | $12K | |
| 0124A | <1% | 1,091 | $12K | |
| 73140 | <1% | 1,600 | $12K | |
| 83880 | <1% | 4,575 | $11K | |
| 95911 | <1% | 38 | $11K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 339 | $11K |
| 87340 | <1% | 3,346 | $11K | |
| 90480 | <1% | 1,030 | $11K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 183 | $11K |
| 64495 | <1% | 2,311 | $11K | |
| 64494 | <1% | 3,288 | $11K | |
| 82784 | <1% | 1,798 | $10K | |
| 86140 | <1% | 8,077 | $10K | |
| 86618 | <1% | 2,164 | $9K | |
| 58301 | <1% | 43 | $9K | |
| 86480 | <1% | 202 | $9K | |
| 97035 | <1% | 1,842 | $9K | |
| 97163 | <1% | 299 | $8K | |
| 86706 | <1% | 1,491 | $8K | |
| 81511 | <1% | 133 | $8K | |
| 76870 | <1% | 229 | $8K | |
| 73560 | <1% | 1,002 | $7K | |
| 92551 | <1% | 893 | $7K | |
| 98927 | <1% | 1,324 | $7K | |
| 29075 | <1% | 41 | $7K | |
| 82950 | <1% | 1,525 | $7K | |
| 73564 | <1% | 1,002 | $7K | |
| 70491 | <1% | 59 | $7K | |
| 59430 | <1% | 41 | $7K | |
| 94726 | <1% | 291 | $7K | |
| 87186 | <1% | 6,719 | $6K | |
| 73080 | <1% | 917 | $6K | |
| 86038 | <1% | 1,229 | $6K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 943 | $6K |
| 83001 | <1% | 493 | $6K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,414 | $5K |
| 84146 | <1% | 519 | $5K | |
| 70498 | <1% | 1,239 | $5K | |
| 83516 | <1% | 912 | $5K | |
| 73590 | <1% | 607 | $5K | |
| 85652 | <1% | 6,130 | $5K | |
| 0071A | <1% | 616 | $5K | |
| 86704 | <1% | 815 | $5K | |
| 82043 | <1% | 3,780 | $5K | |
| 87046 | <1% | 452 | $5K | |
| 90662 | <1% | 1,548 | $5K | |
| 99223 | Prolong inpt eval add15 m | <1% | 97 | $5K |
| 82785 | <1% | 578 | $5K | |
| 72040 | <1% | 277 | $5K | |
| 90716 | <1% | 1,953 | $5K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 983 | $5K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,492 | $5K |
| 84425 | <1% | 380 | $4K | |
| 81025 | <1% | 3,994 | $4K | |
| 82947 | <1% | 1,624 | $4K | |
| 99173 | <1% | 1,703 | $4K | |
| 64415 | <1% | 60 | $4K | |
| 81001 | <1% | 15,805 | $4K | |
| 72110 | <1% | 130 | $4K | |
| 0052A | <1% | 144 | $4K | |
| 87077 | <1% | 7,110 | $4K | |
| 84153 | <1% | 690 | $4K | |
| 96132 | <1% | 22 | $4K | |
| 90734 | <1% | 2,386 | $4K | |
| 86850 | <1% | 4,181 | $4K | |
| 87493 | <1% | 448 | $4K | |
| 0072A | <1% | 518 | $4K | |
| 84402 | <1% | 247 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,520 | $4K |
| 83690 | <1% | 11,309 | $3K | |
| 83721 | <1% | 1,006 | $3K | |
| 82670 | <1% | 196 | $3K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 121 | $3K |
| 90739 | <1% | 29 | $3K | |
| 84100 | <1% | 2,704 | $3K | |
| 11102 | <1% | 56 | $3K | |
| 99403 | <1% | 63 | $3K | |
| 99402 | <1% | 169 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,096 | $3K |
| 73100 | <1% | 478 | $3K | |
| 86762 | <1% | 1,733 | $3K | |
| 85018 | <1% | 4,994 | $3K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 50 | $3K |
| 71101 | <1% | 545 | $3K | |
| 20550 | <1% | 26 | $3K | |
| 88342 | <1% | 1,371 | $3K | |
| 80164 | <1% | 665 | $3K | |
| 86364 | <1% | 538 | $3K | |
| 83993 | <1% | 199 | $3K | |
| G0378 | Hospital observation service, per hour | <1% | 2,970 | $3K |
| 29405 | <1% | 20 | $3K | |
| 0004A | <1% | 968 | $3K | |
| 0051A | <1% | 104 | $3K | |
| 81003 | <1% | 17,383 | $3K | |
| 72070 | <1% | 87 | $3K | |
| 80050 | General health panel | <1% | 151 | $2K |
| 99385 | <1% | 39 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 69 | $2K |
| 93296 | <1% | 165 | $2K | |
| 93308 | <1% | 27 | $2K | |
| 87469 | <1% | 378 | $2K | |
| 87468 | <1% | 377 | $2K | |
| 0081A | <1% | 162 | $2K | |
| 99496 | <1% | 82 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 996 | $2K |
| 82550 | <1% | 1,636 | $2K | |
| 87427 | <1% | 458 | $2K | |
| 84550 | <1% | 1,511 | $2K | |
| 86481 | <1% | 64 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,547 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,747 | $2K |
| 82565 | <1% | 1,088 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12,935 | $2K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 101 | $2K |
| 11100 | <1% | 15 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,846 | $2K |
| 84703 | <1% | 2,477 | $2K | |
| 0134A | <1% | 209 | $2K | |
| 85730 | <1% | 1,997 | $2K | |
| 87045 | <1% | 464 | $2K | |
| 72131 | <1% | 81 | $2K | |
| 0082A | <1% | 115 | $2K | |
| 84165 | <1% | 596 | $2K | |
| 87536 | <1% | 62 | $2K | |
| 93976 | <1% | 20 | $2K | |
| 86431 | <1% | 705 | $2K | |
| 90619 | <1% | 903 | $2K | |
| 90681 | <1% | 3,046 | $2K | |
| 90715 | <1% | 6,778 | $1K | |
| 80178 | <1% | 728 | $1K | |
| 80074 | <1% | 111 | $1K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 38 | $1K |
| 87209 | <1% | 136 | $1K | |
| 12011 | <1% | 80 | $1K | |
| 72050 | <1% | 31 | $1K | |
| 90744 | <1% | 3,876 | $1K | |
| 80069 | <1% | 558 | $1K | |
| 99397 | <1% | 92 | $1K | |
| 20605 | <1% | 13 | $1K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 77 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,430 | $1K |
| 51798 | <1% | 208 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 3,132 | $1K |
| 0154A | <1% | 87 | $1K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 84 | $1K |
| 73090 | <1% | 178 | $1K | |
| 93226 | <1% | 621 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,214 | $1K |
| 52000 | <1% | 12 | $985.85 | |
| 11981 | <1% | 12 | $975.90 | |
| 82570 | <1% | 694 | $973.39 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 66 | $961.85 |
| 73070 | <1% | 84 | $916.62 | |
| 84460 | <1% | 293 | $908.48 | |
| 0031A | <1% | 26 | $867.72 | |
| 96160 | <1% | 37 | $858.98 | |
| 94664 | <1% | 134 | $852.90 | |
| 85379 | <1% | 3,380 | $850.07 | |
| 93922 | <1% | 36 | $846.52 | |
| 84156 | <1% | 781 | $834.71 | |
| 87205 | <1% | 2,578 | $819.31 | |
| 84484 | <1% | 16,083 | $816.87 | |
| 90710 | <1% | 1,890 | $810.90 | |
| 72170 | <1% | 40 | $806.50 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,896 | $791.09 |
| 80305 | <1% | 782 | $778.70 | |
| 0064A | <1% | 129 | $777.51 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 2,606 | $649.15 |
| 88304 | <1% | 671 | $626.83 | |
| 86682 | <1% | 63 | $618.76 | |
| 93246 | <1% | 115 | $614.56 | |
| 87177 | <1% | 117 | $610.98 | |
| 93923 | <1% | 12 | $593.24 | |
| 64636 | <1% | 687 | $567.37 | |
| 88112 | <1% | 57 | $545.08 | |
| 0083A | <1% | 49 | $540.60 | |
| 87040 | <1% | 2,839 | $529.68 | |
| 74022 | <1% | 146 | $517.17 | |
| 86787 | <1% | 48 | $502.32 | |
| 73521 | <1% | 25 | $487.67 | |
| 86580 | <1% | 44 | $477.11 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 14 | $476.15 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,787 | $463.57 |
| 98926 | <1% | 160 | $461.89 | |
| 96367 | <1% | 12 | $458.91 | |
| 12002 | <1% | 75 | $451.58 | |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | <1% | 3,659 | $447.09 |
| 94729 | <1% | 1,220 | $439.19 | |
| 83020 | <1% | 43 | $437.58 | |
| 87505 | <1% | 15 | $423.31 | |
| 84163 | <1% | 40 | $421.40 | |
| 82533 | <1% | 40 | $404.00 | |
| 99221 | <1% | 15 | $403.80 | |
| 84481 | <1% | 50 | $398.44 | |
| 87081 | <1% | 414 | $394.68 | |
| G0176 | Activity therapy, such as music, dance, art or play therapies not for recreation, related to the care and treatment of patient's disabling mental health problems, per session (45 minutes or more) | <1% | 4,293 | $366.40 |
| 83615 | <1% | 249 | $356.04 | |
| 80306 | <1% | 1,742 | $345.23 | |
| 86617 | <1% | 76 | $344.26 | |
| 82465 | <1% | 82 | $340.65 | |
| 83002 | <1% | 40 | $334.40 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,517 | $331.28 |
| 87210 | <1% | 1,057 | $324.12 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 5,191 | $323.18 |
| 87420 | <1% | 865 | $321.70 | |
| 83605 | <1% | 3,879 | $311.44 | |
| 73660 | <1% | 42 | $304.62 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,415 | $289.44 |
| G0238 | Therapeutic procedures to improve respiratory function, other than described by g0237, one on one, face to face, per 15 minutes (includes monitoring) | <1% | 18 | $286.41 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,351 | $284.05 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,191 | $282.90 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 720 | $276.85 |
| 73620 | <1% | 84 | $263.28 | |
| 82040 | <1% | 327 | $255.91 | |
| 81002 | <1% | 1,793 | $255.82 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 15 | $253.29 |
| 85007 | <1% | 824 | $242.81 | |
| 82105 | <1% | 27 | $231.02 | |
| 87338 | <1% | 26 | $221.10 | |
| 86308 | <1% | 316 | $220.38 | |
| 96376 | <1% | 3,409 | $217.72 | |
| 82805 | <1% | 627 | $197.57 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,771 | $194.50 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 893 | $193.78 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,278 | $192.12 |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 25 | $189.78 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 3,106 | $177.52 |
| 90688 | <1% | 14 | $172.53 | |
| 0074A | <1% | 54 | $169.50 | |
| 84450 | <1% | 79 | $163.57 | |
| 87529 | <1% | 30 | $157.72 | |
| 82103 | <1% | 43 | $155.13 | |
| 86360 | <1% | 38 | $148.61 | |
| 82150 | <1% | 99 | $146.82 | |
| 91322 | <1% | 128 | $145.92 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,433 | $142.77 |
| 82248 | <1% | 46 | $141.83 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,145 | $134.52 |
| 11721 | <1% | 12 | $132.90 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,087 | $123.81 |
| 86359 | <1% | 38 | $123.18 | |
| 87634 | <1% | 63 | $121.32 | |
| 84520 | <1% | 148 | $120.62 | |
| 87207 | <1% | 20 | $119.80 | |
| 86334 | <1% | 17 | $107.83 | |
| C1769 | Guide wire | <1% | 707 | $105.08 |
| 93270 | <1% | 12 | $104.97 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 15,295 | $101.14 |
| 83525 | <1% | 15 | $92.44 | |
| 86901 | <1% | 4,095 | $91.47 | |
| 93242 | <1% | 25 | $88.53 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,174 | $84.46 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,612 | $79.71 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 3,149 | $78.81 |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 421 | $76.27 |
| 0003A | <1% | 28 | $75.90 | |
| 87484 | <1% | 69 | $73.68 | |
| 83521 | <1% | 14 | $69.30 | |
| 86765 | <1% | 15 | $67.30 | |
| 84155 | <1% | 101 | $66.60 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,752 | $66.01 |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 25 | $65.34 |
| 84466 | <1% | 12 | $65.25 | |
| 83010 | <1% | 13 | $64.30 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 760 | $57.20 |
| 85045 | <1% | 38 | $56.99 | |
| 86039 | <1% | 12 | $56.05 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 242 | $54.39 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 318 | $52.13 |
| 80175 | <1% | 13 | $49.64 | |
| 69210 | <1% | 13 | $45.18 | |
| 88341 | <1% | 38 | $43.79 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 996 | $37.68 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 310 | $37.65 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 348 | $37.45 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 624 | $31.87 |
| 95886 | <1% | 766 | $30.08 | |
| 80177 | <1% | 15 | $27.97 | |
| 85014 | <1% | 80 | $24.48 | |
| 87807 | <1% | 59 | $23.42 | |
| 29125 | <1% | 26 | $23.33 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 216 | $22.55 |
| 80051 | <1% | 12 | $21.51 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 23 | $19.62 |
| J1815 | Injection, insulin, per 5 units | <1% | 2,375 | $18.47 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,053 | $16.16 |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 164 | $15.28 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,171 | $14.80 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,457 | $14.73 |
| 83986 | <1% | 41 | $14.24 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,262 | $12.26 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,924 | $10.82 |
| 82272 | <1% | 16 | $6.66 | |
| 90474 | <1% | 3,133 | $5.37 | |
| 81000 | <1% | 249 | $4.80 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 519 | $4.14 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 27 | $0.00 |
| J2372 | Injection, phenylephrine hydrochloride (biorphen), 20 micrograms | 0% | 392 | $0.00 |
| 36416 | 0% | 9,154 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 248 | $0.00 |
| 90698 | 0% | 6,798 | $0.00 | |
| 90696 | 0% | 1,776 | $0.00 | |
| A6454 | Self-adherent bandage, elastic, non-knitted/non-woven, width greater than or equal to three inches and less than five inches, per yard | 0% | 428 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 233 | $0.00 |
| J3490 | Unclassified drugs | 0% | 648 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 253 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 238 | $0.00 |
| 93320 | 0% | 284 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 132 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 134 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 150 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 195 | $0.00 |
| Q2039 | Influenza virus vaccine, not otherwise specified | 0% | 85 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 125 | $0.00 |
| A4627 | Spacer, bag or reservoir, with or without mask, for use with metered dose inhaler | 0% | 82 | $0.00 |
| 91307 | 0% | 1,085 | $0.00 | |
| 64492 | 0% | 159 | $0.00 | |
| 91305 | 0% | 834 | $0.00 | |
| 91306 | 0% | 30 | $0.00 | |
| 91315 | 0% | 70 | $0.00 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 0% | 118 | $0.00 |
| 82803 | 0% | 12 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 76 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 75 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 40 | $0.00 |
| 90632 | 0% | 25 | $0.00 | |
| 88307 | 0% | 24 | $0.00 | |
| 91318 | 0% | 35 | $0.00 | |
| 91301 | 0% | 1,639 | $0.00 | |
| 96368 | 0% | 25 | $0.00 | |
| 91317 | 0% | 36 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 18 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 12 | $0.00 |
| 91303 | 0% | 25 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 2,658 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 265 | $0.00 |
| 91308 | 0% | 369 | $0.00 | |
| 91300 | 0% | 2,413 | $0.00 | |
| 90633 | 0% | 4,190 | $0.00 | |
| 91321 | 0% | 211 | $0.00 | |
| 81329 | 0% | 338 | $0.00 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 325 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 234 | $0.00 |
| 76942 | 0% | 111 | $0.00 | |
| 90714 | 0% | 64 | $0.00 | |
| 90707 | 0% | 2,006 | $0.00 | |
| 82009 | 0% | 216 | $0.00 | |
| 93325 | 0% | 372 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 722 | $0.00 |
| 90713 | 0% | 144 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 213 | $0.00 |
| 64491 | 0% | 316 | $0.00 | |
| 36600 | 0% | 12 | $0.00 | |
| 77002 | 0% | 16 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 64 | $0.00 |
| 90671 | 0% | 1,254 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 612 | $0.00 |
| 91313 | 0% | 105 | $0.00 | |
| 91312 | 0% | 684 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 670 | $0.00 |
| 82375 | 0% | 13 | $0.00 | |
| 82140 | 0% | 15 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 22 | $0.00 |
| 90685 | 0% | 165 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 18 | $0.00 |
| 94727 | 0% | 13 | $0.00 | |
| 90672 | 0% | 27 | $0.00 | |
| 87400 | 0% | 42 | $0.00 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialINZANA, LUGENE (CFO & ASSOCIATE CFO)
| Provider | Location | Paid |
|---|---|---|
| Mainehealth | Portland, ME | $142.72M |
| Mainehealth | Portland, ME | $115.05M |
| Mainehealth | Brunswick, ME | $40.06M |
| Mainehealth | Farmington, ME | $22.62M |
| Mainehealth | Biddeford, ME | $10.89M |
| Mainehealth | Falmouth, ME | $6.54M |
| Mainehealth | Portland, ME | $5.46M |
| Mainehealth | Scarborough, ME | $5.04M |
| Mainehealth | Rockport, ME | $4.34M |
| Mainehealth | Scarborough, ME | $4.16M |
| Mainehealth | Portland, ME | $4.09M |
| Mainehealth | Scarborough, ME | $3.94M |
| Mainehealth | Portland, ME | $3.55M |
| Mainehealth | Waldoboro, ME | $3.43M |
| Mainehealth | Scarborough, ME | $3.18M |
| Mainehealth | Brunswick, ME | $2.77M |
| Mainehealth | Portland, ME | $2.68M |
| Mainehealth | Falmouth, ME | $2.10M |
| Mainehealth | Portland, ME | $1.87M |
| Mainehealth | Cape Elizabeth, ME | $1.82M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.